Biblio Discovery — Demo Discovery Service

9 hasil untuk "F. Autore"

Menampilkan 1–9 · 0,48 detik · RSS

  1. Artikel Jurnal

    P115 | CUTANEOUS INVOLVEMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA: REAL-WORLD OUTCOMES WITH VENETOCLAX-OBINUTUZUMAB AT FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS.

    I. Innocenti; A. Tomasso *; L. Stirparo * dkk.

    Haematologica, Vol. 110 No. s1 · 2025 · Inggris · DOAJ Scopus

    Introduction: Cutaneous manifestations are rare in patients with chronic lymphocytic leukaemia (CLL) and may result from either direct leukemic infiltration or the general predisposition of CLL patients to secondary conditions. Leukaemia cutis (LC), caused by skin infiltration of leukemic cells, is…

  2. Artikel Jurnal

    P123 | IBRUTINIB AND VENETOCLAX IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS OUTSIDE CLINICAL TRIALS: A SINGLE-CENTER REAL-WORLD EXPERIENCE

    A. Tomasso; I. Innocenti *; L. Stirparo * dkk.

    Haematologica, Vol. 110 No. s1 · 2025 · Inggris · DOAJ Scopus

    Introduction: The combination of ibrutinib, a Bruton's tyrosine kinase inhibitor, and venetoclax, a BCL-2 inhibitor, has shown synergistic efficacy in chronic lymphocytic leukemia (CLL). Pivotal trials like CAPTIVATE and GLOW report high rates of complete remission (CR) and undetectable minimal…

  3. Artikel Jurnal

    P106 | ONCOGERIATRIC ASSESSMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS OVER 65 YEARS IN TARGET ERA. A MONOCENTRIC PILOT STUDY AT FONDAZIONE POLICLINICO A. GEMELLI, ROME

    I. Innocenti; L. Stirparo; A. Tomasso dkk.

    Haematologica, Vol. 110 No. s1 · 2025 · Inggris · DOAJ Scopus

    Introduction: Chronic lymphocytic leukemia (CLL) primarily affects elderly adults. While targeted agents such as BTKi and BCL-2 inhibitors have improved outcomes, their use in elderly patients raises concerns regarding tolerance and toxicity, and there is still no established method for defining…

  4. Artikel Jurnal

    P120 | CHRONIC LYMPHOCYTIC LEUKEMIA AND RENAL CELL CARCINOMA: A CASE SERIES OF TWELVE PATIENTS

    T. Quaranta; F. Guglielmi; A. Tomasso dkk.

    Haematologica, Vol. 110 No. s1 · 2025 · Inggris · DOAJ Scopus

    Background: Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults, with a median age at diagnosis of 72 years. CLL patients (pts) have an increased risk of second malignancies due to multiple synergistic factors: genetic, environmental, treatment-induced and immunomodulatory…

  5. Artikel Jurnal

    C078 | COMPARISON BETWEEN BTKIS, DRC, BR AND OTHER CHEMO-IMMUNOTHERAPEUTIC SCHEMES IN TERMS OF INFECTIONS AND NEED OF HOSPITALIZATION IN WALDENSTRÖM MACROGLOBULINEMIA

    F. Autore; A.M. Frustaci; V. Peri dkk.

    Haematologica, Vol. 110 No. s1 · 2025 · Inggris · DOAJ Scopus

    Infections are a major source of morbidity and mortality in patients (pts) with Waldenström Macroglobulinaemia (WM). Treatments with Bruton’s Tyrosine Kinase inhibitors (BTKis) have increased, with a reduction on infection rate but data on infection incidence are generally extrapolated from…

  6. Artikel Jurnal

    DP032 | CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND PREVIOUS PNEUMONIA HAVE AN IMPACT ON INFECTIOUS COMPLICATIONS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH ACALABRUTINIB AND ZANUBRUTINIB: A MULTICENTRE SEIFEM STUDY.

    F. Autore; A. Visentin; L. Schiattone dkk.

    Haematologica, Vol. 110 No. s1 · 2025 · Inggris · DOAJ Scopus

    Infections are a major source of morbidity and mortality in patients (pts) with Chronic Lymphocytic Leukemia (CLL). The aim of our study is to describe in a real-world setting the infectious complications in pts with CLL treated with second generation Bruton’s Tyrosine Kinase inhibitors (BTKis)…

  7. Artikel Jurnal

    DP046 | ABSENCE OF LYMPHOCYTOSIS INCREASE AFTER STARTING TREATMENT WITH CBTKI IS UNUSUAL AND ASSOCIATED TO SPECIFIC BIOLOGICAL MARKERS

    A. Mosca; I. Innocenti; A. Tomasso dkk.

    Haematologica, Vol. 110 No. s1 · 2025 · Inggris · DOAJ Scopus

    Background: Bruton tyrosine kinase inhibitors (BTKi) are a class of drugs that have revolutionized Chronic Lymphocytic Leukemia (CLL) therapy. They inhibit Bruton tyrosine kinase (BTK), an enzyme able to trigger a lot of metabolic ways involved in B lymphocytes surviving, proliferation and…